Large Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Gilead Sciences
GILD
$184B
| $184B | $148.77 | 1.38% |
|
2
Pfizer
PFE
$163B
| $163B | $28.57 | 2.15% |
|
3
Bristol-Myers Squibb
BMY
$139B
| $139B | $67.92 | 0.95% |
|
4
Sanofi
SNY
$110B
| $110B | $46.02 | 0.72% |
|
5
GSK
GSK
$104B
| $104B | $52.07 | 0.56% |
|
6
Biogen
BIIB
$32.6B
| $32.6B | $220.77 | 1.21% |
|
Large Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 6 large cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap between $10B and $200B — worth a combined $733B.
The largest by market cap are Gilead Sciences (GILD) at $184B, Pfizer (PFE) at $163B and Bristol-Myers Squibb (BMY) at $139B.
Among institutional investors, Biogen (BIIB) drew the most net new fund positions in Q2 2026: 125 funds opened new positions, taking total fund holders up 29 (2.9%) quarter-over-quarter.
- Combined market cap: $733B across 6 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Gilead Sciences (GILD), $184B market cap.
- Most net new fund positions in Q2 2026: Biogen (BIIB), +29 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.